The 5 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 21.00, with a high estimate of 26.00 and a low estimate of 12.00. The median estimate represents a +199.15% increase from the last price of 7.02.
The current consensus among 5 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.42
Reporting Date May 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.